ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年01月11日 11時00分
Source:
Eisai
エーザイ、中国の新蘇州工場において固体剤生産棟が竣工
東京, 2018年01月11日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、中国子会社である衛材(中国)薬業有限公司(Eisai China Inc.)が、蘇州工業園区内の新蘇州工場において、固体剤生産棟と管理棟を竣工しましたのでお知らせします。
当社は、中国における患者様貢献拡大に向けた製品のさらなる安定供給体制の強化および生産効率の向上を企図し、現蘇州工場(固体剤生産工場)の 5 倍以上の敷地面積を擁する新たな工場用地にて、新蘇州工場の整備を進めています。2014 年 11 月には、注射剤生産棟を竣工し、「メチコバール(R)」注射剤の生産を行っています。今回、新たに竣工した固体剤生産棟は、地上 3 階建て、延べ床面積20,240m2 となり、現蘇州工場の約 2 倍の生産能力(製剤約 30 億錠・包装約 50 億錠/年)を有します。2018 年度下期の稼動を予定しており、「メチコバール」、「アリセプト(R)」、「パリエット(R)」など中国国内向けの固体剤の製剤、包装を行います。新蘇州工場での固体剤生産の本格稼働後、現工場は閉鎖します。
当社における中国事業は、日本・米国に次ぐ規模を有する中核事業であり、このたびの新蘇州工場固体剤生産棟の竣工により、中国国内での自社生産機能の強化および高品質な医薬品の安定供給体制の拡充をはかり、中国市場における患者様とそのご家族のベネフィット向上に貢献してまいります。
本リリースの詳細は下記をご参照ください。
http://www.eisai.co.jp/news/news201803pdf.pdf
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 04, 2026 18:00 JST
Mitsubishi Heavy Industries Announces Large Order Intake, Revenue, and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2026 17:13 JST
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 04, 2026 13:30 JST
Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency
Feb 04, 2026 11:32 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2026 19:36 JST
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST
SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST
TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST
MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST
Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
More Press release >>